Inventor · disambiguated record
John L. Magnani
Also filed as: MAGNANI JOHN L · MAGNANI JOHN LOUIS
48 granted patents·48 pending applications·850 citations·filing 1994–2023
98Inventor score
Top patents by PatentIndex Score
96 records- 0197US8039442B2Compounds and methods for treatment of sickle cell disease or complications associated therewithGLYCOMIMETICS INC·Filed 2008·Granted Oct 18, 2011·23 cites·5 claims
- 0296USRE44778EHeterobifunctional pan-selectin inhibitorsMAGNANI JOHN L·Filed 2012·Granted Feb 25, 2014·30 cites·17 claims
- 0396US8361975B2Compounds and methods for treatment of sickle cell or complications associated therewithGLYCOMIMETICS INC·Filed 2011·Granted Jan 29, 2013·20 cites·6 claims
- 0495US9109002B2E-selectin antagonist compounds, compositions, and methods of useGLYCOMIMETICS INC·Filed 2012·Granted Aug 18, 2015·32 cites·15 claims
- 0595US8410066B2Heterobifunctional inhibitors of E-selectins and CXCR4 chemokine receptorsMAGNANI JOHN L·Filed 2010·Granted Apr 2, 2013·31 cites·33 claims
- 0695US7989601B2Heterobifunctional pan-selectin inhibitorsGLYCOMIMETICS INC·Filed 2010·Granted Aug 2, 2011·28 cites·15 claims
- 0795US7728117B2Heterobifunctional pan-selectin inhibitorsGLYCOMIMETICS INC·Filed 2006·Granted Jun 1, 2010·29 cites·1 claims
- 0894US9867841B2Compounds, compositions and methods using E-selectin antagonists for mobilization of hematopoietic cellsGLYCOMIMETICS INC·Filed 2013·Granted Jan 16, 2018·13 cites·13 claims
- 0994US7741312B2Compounds and methods for inhibiting selectin-mediated functionGLYCOMIMETICS INC·Filed 2006·Granted Jun 22, 2010·29 cites·4 claims
- 1094US7517980B2Glycomimetric inhibitors of the PA-IL lectin, PA-IIL lectin or both the lectins from PseudomonasGLYCOMIMETICS INC·Filed 2006·Granted Apr 14, 2009·21 cites·2 claims
- 1193US9796745B2E-selectin antagonist compounds, compositions, and methods of useGLYCOMIMETICS INC·Filed 2015·Granted Oct 24, 2017·12 cites·8 claims
- 1293US8633303B2Heterobifunctional pan-selectin inhibitorsMAGNANI JOHN L·Filed 2011·Granted Jan 21, 2014·21 cites·19 claims
- 1393US8530448B2Compounds and methods for inhibiting selectin-mediated functionMAGNANI JOHN L·Filed 2010·Granted Sep 10, 2013·21 cites·13 claims
- 1492US8258290B2Glycomimetic inhibitors of the PA-IL lectin, PA-IIL lectin or both the lectins from pseudomonasMAGNANI JOHN L·Filed 2009·Granted Sep 4, 2012·23 cites·6 claims
- 1592US8026222B2Methods of use of glycomimetics with replacements for hexoses and n-acetyl hexosaminesGLYCOMIMETICS INC·Filed 2008·Granted Sep 27, 2011·19 cites·12 claims
- 1692US7060685B2Compounds and methods for inhibiting selectin-mediated functionGLYCOMIMETICS INC·Filed 2003·Granted Jun 13, 2006·44 cites·9 claims
- 1791US11332491B2E-selectin antagonist compounds, compositions, and methods of useGLYCOMIMETICS INC·Filed 2020·Granted May 17, 2022·2 cites·14 claims
- 1891US10766916B2E-selectin antagonist compounds, compositions, and methods of useGLYCOMIMETICS INC·Filed 2019·Granted Sep 8, 2020·3 cites·16 claims
- 1991US9534009B2Pan-selectin inhibitor with enhanced pharmacokinetic activityGLYCOMIMETICS INC·Filed 2014·Granted Jan 3, 2017·16 cites·7 claims
- 2091US8895510B2Pan-selectin inhibitor with enhanced pharmacokinetic activityMAGNANI JOHN L·Filed 2009·Granted Nov 25, 2014·18 cites·13 claims
- 2191US8518896B2Treatment of cancers of the blood using selected glycomimetic compoundsMAGNANI JOHN L·Filed 2009·Granted Aug 27, 2013·20 cites·7 claims
- 2288US10526361B2E-selectin antagonist compounds, compositions, and methods of useGLYCOMIMETICS INC·Filed 2017·Granted Jan 7, 2020·5 cites·18 claims
- 2388US6465434B1Methods and compositions for the inhibition of cancer metastasis mediated by endothelial adhesion moleculesUNIV STANFORD·Filed 1999·Granted Oct 15, 2002·49 cites·4 claims
- 2487US11780873B2Highly potent multimeric e-selectin antagonistsGLYCOMIMETICS INC·Filed 2021·Granted Oct 10, 2023·1 cites·42 claims
- 2587US7964569B2Glycomimetic replacements for hexoses and N-acetyl hexosaminesGLYCOMIMETICS INC·Filed 2007·Granted Jun 21, 2011·19 cites·13 claims
- 2687US7361644B2Specific antagonist for both E- and P-selectinsGLYCOMIMETICS INC·Filed 2004·Granted Apr 22, 2008·25 cites·5 claims
- 2787US6121233AMethods for the inhibition of cancer metastasis mediated by endothelial adhesion moleculesMAGNANI JOHN L·Filed 1994·Granted Sep 19, 2000·59 cites·4 claims
- 2886US11072625B2Highly potent multimeric e-selectin antagonistsGLYCOMIMETICS INC·Filed 2017·Granted Jul 27, 2021·4 cites·35 claims
- 2984US6387884B1Leukocyte homing modulationUNIV STANFORD·Filed 1994·Granted May 14, 2002·59 cites·3 claims
- 3083US6391857B1Methods and compositions for endothelial bindingUNIV STANFORD·Filed 1994·Granted May 21, 2002·57 cites·5 claims
- 3182US11987598B2E-selectin antagonist compounds, compositions, and methods of useGLYCOMIMETICS INC·Filed 2022·Granted May 21, 2024·0 cites·65 claims
- 3282US11712446B2Methods of mobilizing marrow infiltrating lymphocytes and uses thereofGLYCOMIMETICS INC·Filed 2018·Granted Aug 1, 2023·1 cites·14 claims
- 3382US10519181B2Heterobifunctional inhibitors of E-selectins and CXCR4 chemokine receptorsGLYCOMIMETICS INC·Filed 2015·Granted Dec 31, 2019·4 cites·31 claims
- 3479US11197877B2Galactopyranosyl-cyclohexyl derivauves as E-selectin antagonistsGLYCOMIMETICS INC·Filed 2018·Granted Dec 14, 2021·2 cites·53 claims
- 3579US7135301B2Detection and treatment of prostate cancerGLYCOMIMETICS INC·Filed 2002·Granted Nov 14, 2006·12 cites·2 claims
- 3679US5965457AMethods of screening for a candidate compound able to bind to CD34+ cellsFiled 1995·Granted Oct 12, 1999·44 cites·10 claims
- 3778US2024165139A1Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonistsGLYCOMIMETICS INC·Filed 2023·Application pending·0 cites
- 3876US2023365609A1Highly potent multimeric e-selectin antagonistsGLYCOMIMETICS INC·Filed 2023·Application pending·0 cites
- 3974US11845771B2Heterobifunctional inhibitors of E-selectin and galectin-3GLYCOMIMETICS INC·Filed 2019·Granted Dec 19, 2023·1 cites·61 claims
- 4073US11878026B2Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonistsGLYCOMIMETICS INC·Filed 2021·Granted Jan 23, 2024·0 cites·29 claims
- 4172US2023414642A1Methods of mobilizing marrow infiltrating lymphocytes and uses thereofGLYCOMIMETICS INC·Filed 2023·Application pending·0 cites
- 4272US2024150388A1Heterobifunctional inhibitors of e-selectin and galectin-3GLYCOMIMETICS INC·Filed 2023·Application pending·0 cites
- 4369US2023127765A1Combination of t-cell checkpoint inhibitors with inhibitors of e-selectin or cxcr4, or with heterobifunctional inhibitors of both e-selectin and cxcr4GLYCOMIMETICS INC·Filed 2022·Application pending·0 cites
- 4468US7727735B2Detection and treatment of prostate cancerGLYCOMIMETICS INC·Filed 2006·Granted Jun 1, 2010·1 cites·1 claims
- 4563US6677164B1Multivalent polymers, processes for their preparation, and their use for preparing biologically active compoundsNOVARTIS AG·Filed 1996·Granted Jan 13, 2004·14 cites·13 claims
- 4663US2014178303A1Heterobifunctional pan-selectin inhibitorsGLYCOMIMETICS INC·Filed 2013·Application pending·0 cites
- 4760US11433086B2Combination of T-cell checkpoint inhibitors with inhibitors of e-selectin or CXCR4, or with heterobifunctional inhibitors of both E-selectin and CXCR4GLYCOMIMETICS INC·Filed 2017·Granted Sep 6, 2022·0 cites·12 claims
- 4860US2016289257A1Glycomimetic compounds and methods to inhibit infection by hivGLYCOMIMETICS INC·Filed 2016·Application pending·0 cites
- 4960US2003133937A1Methods and compositions for the inhibition of cancer metastasis mediated by endothelial adhesion moleculesJOHN L MAGNANI·Filed 2002·Application pending·0 cites
- 5059US2024269157A1Compositions and methods for overcoming microenvironment-mediated resistance via e-selectin targetingGLYCOMIMETICS INC·Filed 2022·Application pending·0 cites
Showing the top 50 of 96 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when John L. Magnani files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →